First patient treated in trial of a novel liver dialysis device, DIALIVE


The first patient in an international trial of a new liver dialysis system has been recruited at the Royal Free Hospital in London. The device, called DIALIVE, was invented by scientists and doctors at University College London and Royal Free London NHS Foundation Trust. The principles behind DIALIVE are based on recent advances in the understanding of the mechanisms underlying liver failure, a condition that affects about 200,000-300,000 people every year across Europe. ii This patient group treated in the trial has a greater than 25% chance of death within a 28-day period if they do not undergo a liver transplant.

Twenty-four patients will be included in this first trial, which is aimed at establishing DIALIVE's safety and performance, is being conducted at seven centers across Europe: London, Birmingham, Nottingham, and Edinburgh in the UK, Rostock in Germany, Paris, France, and Madrid, Spain. A second trial that plans to enroll more than 100 patients across Europe is already being designed. That study is scheduled to begin in 2018 and will include patients at another 18 widely distributed European referral hospitals for liver diseases that are part of the European Foundation for the Study of Chronic Liver Failure (EF-Clif) consortium of hospitals. Continue reading


You have the power to SAVE lives.  Register as an organ, eye, and tissue donor
Go to:   |   Social Media Declaration: #OrganDonor
To ensure your gift is honored, share your donation wishes with family and friends